Holen Sie sich die Stockscreener-App
1.60
3.90%
0.06
Handel nachbörslich:
1.62
0.02
+1.25%
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
What drives Milestone Pharmaceuticals Inc. stock priceHigh-return market picks - Autocar Professional
Milestone Pharmaceuticals Inc. Stock Analysis and ForecastConsistently exceptional gains - jammulinksnews.com
What analysts say about Milestone Pharmaceuticals Inc. stockConsistently superior profits - Autocar Professional
Is Milestone Pharmaceuticals Inc. a good long term investmentDynamic portfolio growth - Autocar Professional
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution (MIST) - Seeking Alpha
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Cuts Target Price to $4 - 富途牛牛
HC Wainwright Has Positive Estimate for MIST Q3 Earnings - Defense World
Milestone Pharmaceuticals plunges after pricing $52.5M offering - MSN
What makes Milestone Pharmaceuticals Inc. stock price move sharplyTrade Ready Signal - Newser
Why Milestone Pharmaceuticals Inc. stock attracts strong analyst attention10x Potential Stocks - Newser
How Milestone Pharmaceuticals Inc. stock performs during market volatilityPrecision Entry Strategy - Newser
Retail investors who have a significant stake must be disappointed along with institutions after Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) market cap dropped by US$9.0m - simplywall.st
Milestone Pharmaceuticals shares fall 7.37% intraday after FDA acceptance of CARDAMYST Nasal Spray response. - AInvest
Milestone Pharmaceuticals Announces Public Offering for $48.7M - TipRanks
MIST SEC FilingsMilestone Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Milestone Pharmaceuticals Initiates Capital Raise Through Securities Offering - AInvest
CARDAMYST's Regulatory Odyssey Nears Finish Line: Why Milestone Pharmaceuticals is Poised for Liftoff by Q4 2025 - AInvest
Milestone Pharma's $52.5M Warrant Offering: Betting on FDA Approval and PSVT's Untapped Market - AInvest
Milestone Pharmaceuticals' $52.5M Offering: A Risky Gamble or Strategic Lifeline? - AInvest
Milestone Pharmaceuticals (MIST) Announces $52.5M Public Offerin - GuruFocus
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge - Benzinga
Why Is Milestone Pharmaceuticals Stock Plunging On Friday? - Benzinga
Milestone Pharmaceuticals (MIST) Shares Plummet After $52.5 Mill - GuruFocus
Milestone Pharmaceuticals announces pricing of $52.5 million public offering - MarketScreener
Milestone Pharmaceuticals prices $52.5 million public offering - Investing.com India
Milestone Pharmaceuticals prices $52.5 million public offering By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Pub - GuruFocus
Milestone Pharmaceuticals Plummets 39%—What’s Behind the Freefall? - AInvest
Milestone Pharmaceuticals Shares Drop Sharply After Public Offering Announcement - MSN
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants - TradingView
Milestone Pharmaceuticals Secures $52.5M Funding to Advance Breakthrough PSVT Heart Treatment - Stock Titan
Navigating the Dilution Crossroads: Milestone Pharmaceuticals' Financing – Gateway or Value Trap? - AInvest
Milestone Pharmaceuticals Poised to Break Through with CARDAMYST: A Strategic Play Ahead of FDA's December Decision - AInvest
Milestone Pharmaceuticals stock plunges on public offering announcement By Investing.com - Investing.com Nigeria
4.91%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):